Sanofi's Wayrilz Gets Orphan Drug Tag for IgG4-Related Disease in Japan

Key Takeaways Sanofi secured Japan orphan drug status for Waylirz to treat IgG4-related disease.The tag offers incentives like priority review and tax benefits to aid development.Sanofi is studying Waylirz in late-stage studies for IgG4-RD and other rare diseases.Sanofi (SNY) announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted orphan drug designation to Waylirz (rilzabrutinib) for the treatment of IgG4-related disease (IgG4-RD). The drug is not yet approved for this indication i ...